State of Alaska
Fiscal Note
Bill Version: CSHB 43(JUD)
2018 Legislative Session
Fiscal Note Number: 2
(S) Publish Date: 1/31/2018
Identifier: HB043-DCCED-CBPL-01-19-18 Department: Department of Commerce, Community and
Title: NEW DRUGS FOR THE TERMINALLY ILL Economic Development
Sponsor: GRENN Appropriation: Corporations, Business and Professional
Requester: (S) Health and Social Services Licensing
Allocation: Corporations, Business and Professional
Licensing
OMB Component Number: 2360
Expenditures/Revenues
Note: Amounts do not include inflation unless otherwise noted below. (Thousands of Dollars)
Included in
FY2019 Governor's
Appropriation FY2019 Out-Year Cost Estimates
Requested Request
OPERATING EXPENDITURES FY 2019 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024
Personal Services
Travel
Services
Commodities
Capital Outlay
Grants & Benefits
Miscellaneous
Total Operating 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Fund Source (Operating Only)
None
Total 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Positions
Full-time
Part-time
Temporary
Change in Revenues
None
Total 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Estimated SUPPLEMENTAL (FY2018) cost: 0.0 (separate supplemental appropriation required)
(discuss reasons and fund source(s) in analysis section)
Estimated CAPITAL (FY2019) cost: 0.0 (separate capital appropriation required)
(discuss reasons and fund source(s) in analysis section)
ASSOCIATED REGULATIONS
Does the bill direct, or will the bill result in, regulation changes adopted by your agency? No
If yes, by what date are the regulations to be adopted, amended or repealed? N/A
Why this fiscal note differs from previous version/comments:
Updated to the 2018 Legislative form.
Prepared By: Janey McCullough, Director Phone: (907)465-2538
Division: Corporations, Business and Professional Licensing Date: 01/19/2018 01:00 PM
Approved By: Catherine Reardon, Director Date: 01/19/18
Agency: Division of Administrative Services, DCCED
Printed 1/31/2018 Page 1 of 2 Control Code: xQpCb
 CSHB 43(JUD) - Fiscal Note 2
FISCAL NOTE ANALYSIS
STATE OF ALASKA BILL NO. HB 43
2018 LEGISLATIVE SESSION
Analysis
HB 43 prohibits disciplinary action being taken against physicians by the State Medical Board for prescribing, dispensing, or
administering an investigational drug, biological product, or device to terminally ill patients that have considered all other
treatment options approved by the U.S. Food and Drug Administration and are ineligible or unable to participate in a
current clinical trial.
This legislation establishes immunity for physicians, manufacturers, and distributors in the case of injury or death of a
terminally ill patient from the use or nonuse of an investigational drug, biological product, or device, provided that
informed consent was obtained from the patient and notice of immunity was given in advance.
HB 43 amends the statute limiting the sale and distribution of new drugs so it does not apply to physicians prescribing or
administering investigational drugs under the conditions established in Section 1 of the bill. Additionally, this legislation
prohibits requiring licensed entities subject to AS 47.32.030 to increase services for the sole purpose of accommodating a
physicians practice of prescribing, dispensing, or administering an investigational drug, biological product, or device, or
providing related treatment to a patient.
The Division of Corporations, Business and Professional Licensing does not anticipate fiscal impact from this legislation.
(Revised 9/26/17 OMB/LFD) Page 2 of 2
HB043-DCCED-CBPL-01-19-18 Page 2 of 2 Control Code: xQpCb


Statutes affected:
HB0043A, AM HB 43, introduced 01/18/2017: 08.64.367, 17.20.110, 47.32.030
HB0043B, AM CSHB 43(JUD), introduced 04/05/2017, passed House 04/10/2017, passed Senate 04/25/2018: 08.64.367, 17.20.110, 47.32.030
HB0043Z, AM Enrolled HB 43, introduced 04/25/2018: 08.64.367, 17.20.110, 47.32.030